NCT05929144 Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases
| NCT ID | NCT05929144 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Caen |
| Condition | Memory Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-05-05 |
| Primary Completion | 2028-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-05-05 with a primary completion date of 2028-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Inserm NeuroPresage team has been using MRI for more than 20 years in the study of normal ageing and memory pathologies to further the understanding and the characterization of early diagnosis and the cerebral substrates of cognitive deficits in patients, particularly in the context of neurodegenerative diseases. Two years ago, a new 3T MRI camera was installed at the Cyceron centre. It is more efficient and should make it possible to obtain better quality images and/or to reduce the time required to acquire these images. In this context, it seems important to test the different sequences that we classically use in our studies, or that we plan to implement in our next studies (learning and text retrieval fMRI task), in order to optimize them, with a view to integrating them in our future studies.
Eligibility Criteria
Inclusion Criteria: * Healthy volunteers of legal age * Affiliation with a social security scheme or beneficiary of such a scheme * Signing of the protocol informed consent * For women of childbearing age or capacity, a urine pregnancy test before inclusion Exclusion Criteria: * Protected persons in accordance with articles L. 1121-5 to L.1121-8 of the Public Health Code: protected adults, pregnant and nursing women * Presence of contraindications to MRI examination without contrast agents injection * Presence of a chronic neurological or psychiatric condition (including substance use disorder) * History of brain disease (vascular, degenerative, malformative, tumour, or head trauma with loss of consciousness for more than one hour) * Current or recent use of medications that may interfere with imaging (psychotropic drugs, antihistamines with anticholinergic action, antiparkinsonian drugs, benzodiazepines including muscle relaxants, long-term steroidal anti-inflammatory drugs, antiepileptic drugs, central painkillers)
Contact & Investigator
Gaël Chételat, PhD
STUDY DIRECTOR
Institut National de la Santé Et de la Recherche Médicale, France
Frequently Asked Questions
Who can join the NCT05929144 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Memory Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05929144 currently recruiting?
Yes, NCT05929144 is actively recruiting participants. Contact the research team at poisnel@cyceron.fr for enrollment information.
Where is the NCT05929144 trial being conducted?
This trial is being conducted at Caen, France.
Who is sponsoring the NCT05929144 clinical trial?
NCT05929144 is sponsored by University Hospital, Caen. The principal investigator is Gaël Chételat, PhD at Institut National de la Santé Et de la Recherche Médicale, France. The trial plans to enroll 40 participants.